$1.34
+0.38 (+38.95%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where BIVI is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
6 interventional · 1 with posted results
Held by 3 tracked-famous managers (RENAISSANCE TECHNOLOGIES LLC, CITADEL ADVISORS LLC, JANE STREET GROUP, LLC) · FINRA short interest 4.4 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| NE3107 in Adults With Neurological Symptoms of Long COVIDNCT06847191Change from Baseline in performance on the Cogstate Cognition battery*Randomized · Triple-masked · Treatment | Phase 2 | Active, not recruiting | Drug: NE3107, Placebo | Long COVID | 203 | Aug 2026 | ≤ 11 d | 2026-05-29 |
| A Study of NE3107 in Early Parkinson'sNCT06757010Monocyte Lymphocyte Ratio (MLR)Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: NE3107, Placebo | Parkinsons Disease (PD) | 57 | 2026-05-01actual | — | 2026-08-11 |
| A Phase 3 Study of NE3107 in Probable Alzheimer's DiseaseNCT04669028Change in Clinical Dementia Rating Scale Sum of Boxes (CDR-SB)Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: NE3107, Placebo | Alzheimer Disease | 439 | 2023-09-30actual | — | 2023-11-21 |
| A Study for Evaluation of BIV201 to Reduce Ascites and Complications in Patients With Cirrhosis and Refractory AscitesNCT04112199Incidence of complications, at least grade 2 severityRandomized · Open-label · Treatment | Phase 2 | Terminatedsponsor's stated reason: For reasons unrelated to safety or efficacy | Drug: BIV201 continuous infusion | Ascites, Decompensated Cirrhosis | 15 | 2023-05-08actual | — | 2024-05-08 |
| NE3107 Activity and Safety in Patients With Parkinson's Disease Using LevodopaNCT05083260Change from baseline (day 1) in Motor disease society- Unified Parkinson's disease rating scale Part III total score for the patient in the "off-state" (without L-dopa for previous eight hours)Randomized · Quadruple-masked · Treatment | Phase 1/2 | Completed | Drug: NE3107, placebo | Parkinson Disease | 46 | 2022-11-21actual | — | 2023-02-08 |
| Continuous Infusion Terlipressin for Patients With Cirrhosis and Refractory AscitesNCT03107091results2021-07-13Clinical Safety of Terlipressin Infusion in Cirrhotic Patients With Refractory AscitesOpen-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Terlipressin acetate continuous infusion | Cirrhosis, Ascites Hepatic | 6 | 2019-04-01actual | — | 2021-07-13 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19